Current capacity for diagnosing Alzheimer’s disease in Germany and implications for wait times

Background: Amyloid-targeting therapies for Alzheimer’s disease (AD) might become available in Germany soon. The combination of a large pool of prevalent cases and a complex diagnostic process to determine eligibility for these treatments is likely t

Saved in:
Bibliographic Details
Main Authors: Mattke, Soeren (Author) , Tang, Yu (Author) , Hanson, Mark (Author) , von Arnim, Christine A. F. (Author) , Frölich, Lutz (Author) , Grimmer, Timo (Author) , Onur, Oezguer A. (Author) , Perneczky, Robert (Author) , Teipel, Stefan (Author) , Thyrian, Jochen René (Author)
Format: Article (Journal)
Language:English
Published: 08 October 2024
In: Journal of Alzheimer's disease
Year: 2024, Volume: 101, Issue: 4, Pages: 1249-1259
ISSN:1875-8908
DOI:10.3233/JAD-240728
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3233/JAD-240728
Verlag, lizenzpflichtig, Volltext: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad240728
Get full text
Author Notes:Soeren Mattke, Yu Tang, Mark Hanson, Christine A.F. von Arnim, Lutz Frölich, Timo Grimmer, Oezguer A. Onur, Robert Perneczky, Stefan Teipel, Jochen René Thyrian
Description
Summary:Background: Amyloid-targeting therapies for Alzheimer’s disease (AD) might become available in Germany soon. The combination of a large pool of prevalent cases and a complex diagnostic process to determine eligibility for these treatments is likely t
Item Description:Gesehen am 18.03.2025
Physical Description:Online Resource
ISSN:1875-8908
DOI:10.3233/JAD-240728